In the US alone, 1.1 million individuals are living with the progressive neurodegenerative movement disorder, and 90,000 are diagnosed each year.
|Articles|May 4, 2012
Study Questions Quality of Medical Evidence Found in Clinical Trials
Advertisement
Most major medical studies that guide doctors and lead to new treatment advice are not as sound as patients might expect, a new study finds.
The largest analysis of clinical trials to date looked at nearly 41,000 studies and found many fall short when it comes to producing meaningful evidence that should guide medical decision-making.
Read the full story:
Source: CBS News
Advertisement
Related to this article
Baricitinib is now FDA approved for adolescents 12 and older with severe alopecia areata, extending the once-daily pill beyond adults.
A new type of eye drug matched standard anti-VEGF therapy in a large trial for diabetic macular edema, a disease affecting 1.6 million Americans.
Portuguese patch testing finds many chronic hand eczema cases link to allergic contact dermatitis—especially occupational exposures like methylisothiazolinone, HEMA acrylates, thiuram mix, nickel.
Two posters report 3.9% first-year GLP-1 discontinuation and a 5-day median time to first fill under pharmacist-led care.
CDC's Jane Henley, MSPH, explains what's behind falling lung cancer deaths and why 4 in 5 eligible adults still aren't getting screened.
The regulatory decisions reflect how advances in biomarkers and molecular medicine are reshaping both diagnosis and treatment.
As peptides go mainstream, the FDA's shifting rules and a fractured state patchwork leave patients navigating a largely unregulated gray market.
Advertisement
Advertisement
Trending on AJMC
1
NCCN Journal Publishes Guidelines Update in Mantle Cell Lymphoma
2
Health System Pharmacies Keep Patients on GLP-1 Therapy
3
Peptide Regulation Debate Intensifies After FDA Advisory Panel's Controversial Vote
4
Philadelphia Experts Share How Bispecific Delivery in Myeloma Varies by Site
5